An existing drug for HIV could double as a preventative therapy for Alzheimer’s disease, according to researchers. NRTIs (nucleoside reverse transcriptase inhibitors) are antivirals that are ...

These conclusions were stronger in participants who carried the APOE-e4 allele, a genetic risk factor for Alzheimer's disease, suggesting that reducing sedentary time may be especially important ...

As researchers work to improve treatment of Alzheimer's disease, new research by UCLA Health identified a candidate drug that reduces levels of a toxic form of a protein in the brain caused by the ...

In a recent study, researchers found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease who received lecanemab infusions. The Food and Drug ...

WASHINGTON — U.S. health officials on Friday endorsed the first blood test that can help diagnose Alzheimer’s and identify patients who may benefit from drugs that can modestly slow the memory ...

The Food and Drug Administration has greenlit Japan-based test manufacturer Fujirebio to begin marketing its blood test for helping doctors diagnose Alzheimer's disease in some patients ...

Share on Pinterest New research suggests that HIV drugs may have a protective effect against Alzheimer’s. Willie B. Thomas/Getty Images Researchers at UVA Health have found that a class of HIV ...

Last December, Phil Robertson's son Jase Robertson revealed that his father was diagnosed with Alzheimer’s disease. Jase Robertson, 55, announced that his father was in the "early stages" of ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Alzheimer's symptoms and changes in cognitive function typically start to appear after age 65. A new study published in Lancet Regional Health-Americas finds that Alzheimer's symptoms can present ...

Alzheimer’s disease is currently diagnosed with expensive medical imaging or invasive methods that require a spinal tap. Patients now have an alternative. The FDA has cleared a new Fujirebio ...

In a real-world study, infusion-related reactions occurred in 37% of Alzheimer's patients treated with lecanemab. Amyloid-related imaging abnormalities (ARIA) emerged in 22% of treated patients.